Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1000 participants
OBSERVATIONAL
2020-10-01
2024-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding
NCT05624229
Proton Pump Inhibitors and Dysbiosis in Cirrhosis
NCT01458990
Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy
NCT05070351
Medication Adherence in Patients With Liver Cirrhosis
NCT03627338
Acute-On-Chronic Liver Failure In Cirrhotic Patients
NCT04790435
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study aimed to assess the appropriateness of prescribing PPIs to patients with cirrhosis, examining its impact on prescribing practices and identifying associated factors.
in this observational, descriptive, cross-sectional study, cirrhotic patients receiving proton pump inhibitors will be included in the study. Enrolled patients will classified according to the indication for PPI administration: Group A: Inappropriate use of PPI, Group B: Appropriate use of PPI. Use of PPI will be considered inappropriate when prescribed without approved indication or used for a prolonged period beyond the recommended duration. The prevalence of PPI misuse in cirrhotics will be estimated and multivariate analyses will be conducted in order to identify independent predictors of inappropriate use of PPI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Inappropriate use of PPI
PPI is prescribed without approved indication or used for a prolonged period beyond the recommended duration.
No interventions assigned to this group
Appropriate use of PPI
PPI is prescribed for the approved indication and used within the recommended duration.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Liver Institute, Egypt
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gasser I El-Azab, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Liver Institute, Menoufia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Liver institute - Menoufia University
Shibīn al Kawm, Menoufia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
El-Azab G, Zakareya T, Abdel Aleem M, Edrees A. Inappropriate use of proton pump inhibitors in patients with liver cirrhosis: a cross-sectional study. Eur J Gastroenterol Hepatol. 2025 Oct 1;37(10):1141-1146. doi: 10.1097/MEG.0000000000002985. Epub 2025 Apr 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01001099646
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.